Consistent with the widely recognized importance of CD8+ T cells in conferring anti-tumor immunity, depletion studies in conjunction with a DC-specific deletion of FcRn conclusively identified FcRn-mediated cross-presentation as the mechanism by which tumor protection was enabled (98, 113). This evidence concerns the gene CD8A and neoplasm.